MedTrace Logo

Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

NCT04301843 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 131

Last updated 2026-02-03

No results posted yet for this study

Summary

Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.

Conditions

Interventions

DRUG

Eflornithine

DFMO (difluoromethylornithine) will be given at a dose of 1000 mg/m2 BID on each day of study.

Sponsors & Collaborators

  • K C Pharmaceuticals Inc.

    collaborator INDUSTRY

  • Beat NB Cancer Foundation

    collaborator OTHER

  • Team Parker for Life

    collaborator UNKNOWN

  • USWM, LLC

    collaborator UNKNOWN

  • Giselle Sholler

    lead OTHER

Principal Investigators

  • Giselle Sholler, MD · Beat Childhood Cancer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
31 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-25
Primary Completion
2028-10-01
Completion
2033-10-01
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04301843 on ClinicalTrials.gov